Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 431, Issue 2, 2013, Pages 146-151

  Wang, Jing ^a,b   Yang, Qifeng ^a   Haffty, Bruce G ^c   Li, Xiaoyan ^b   Moran, Meena S ^d  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast conservation therapy; Fulvestrant; Hormonal therapy; Radiation; Sequencing

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; KU ANTIGEN; RAD51 PROTEIN; TETRAZOLIUM;

ARTICLE; BREAST CANCER; CANCER CELL; CELL ASSAY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL SURVIVAL; CLINICAL EFFECTIVENESS; COLORIMETRY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-ACTIVATED PROTEIN KINASE; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NUCLEAR PROTEINS; RAD51 RECOMBINASE; RADIATION-SENSITIZING AGENTS; RECEPTORS, ESTROGEN;

EID: 84873456547     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.006     Document Type: Article

References (32)

1. Igene H. Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J. 2008, 14:428-434.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010, CA cancer. J. Clin. 2010, 60:277-300.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
4. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 2010, 19:1893-1907.
5. Bellon J.R., Come S.E., Gelman R.S., Henderson I.C., Shulman L.N., Silver B.J., Harris J.R., Recht A. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J. Clin. Oncol. 2005, 23:1934-1940.
6. Recht A., Come S.E., Henderson I.C., Gelman R.S., Silver B., Hayes D.F., Shulman L.N., Harris J.R. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N. Engl. J. Med. 1996, 334:1356-1361.
7. Albain K.S., Barlow W.E., Ravdin P.M., Farrar W.B., Burton G.V., Ketchel S.J., Cobau C.D., Levine E.G., Ingle J.N., Pritchard K.I., Lichter A.S., Schneider D.J., Abeloff M.D., Henderson I.C., Muss H.B., Green S.J., Lew D., Livingston R.B., Martino S., Osborne C.K. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:2055-2063.
8. Pico C., Martin M., Jara C., Barnadas A., Pelegri A., Balil A., Camps C., Frau A., Rodriguez-Lescure A., Lopez-Vega J.M., De La Haba J., Tres A., Alvarez I., Alba E., Arcusa A., Oltra A., Batista N., Checa T., Perez-Carrion R., Curto J. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann. Oncol. 2004, 15:79-87.
9. Schmidberger H., Hermann R.M., Hess C.F., Emons G. Interactions between radiation and endocrine therapy in breast cancer. Endocr. Relat. Cancer. 2003, 10:375-388.
10. Pierce L.J., Hutchins L.F., Green S.R., Lew D.L., Gralow J.R., Livingston R.B., Osborne C.K., Albain K.S. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J. Clin. Oncol. 2005, 23:24-29.
11. Ahn P.H., Vu H.T., Lannin D., Obedian E., DiGiovanna M.P., Burtness B., Haffty B.G. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J. Clin. Oncol. 2005, 23:17-23.
12. Lynn J. Fulvestrant ('Faslodex') - a new hormonal treatment for advanced breast cancer. Eur. J. Oncol. Nurs. 2004, 8(Suppl. 2):S83-S88.
13. Coser K.R., Chesnes J., Hur J., Ray S., Isselbacher K.J., Shioda T. Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc. Natl. Acad. Sci. USA 2003, 100:13994-13999.
14. Hur J., Bell D.W., Dean K.L., Coser K.R., Hilario P.C., Okimoto R.A., Tobey E.M., Smith S.L., Isselbacher K.J., Shioda T. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer Res. 2006, 66:10153-10161.
15. Franken N.A.P., Rodermond H.M., Stap J., Haveman J., van Bree C. Clonogenic assay of cells in vitro. Nature Protocols 2006, 1:2315-2319.
16. Li X., Kong X., Huo Q., Guo H., Yan S., Yuan C., Moran M.S., Shao C., Yang Q. Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci. 2011, 102:1151-1157.
17. Wazer D.E., Tercilla O.F., Lin P.S., Schmidt-Ullrich R. Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen. Br. J. Radiol. 1989, 62:1079-1083.
18. Villalobos M., Becerra D., Nunez M.I., Valenzuela M.T., Siles E., Olea N., Pedraza V., Ruiz de Almodovar J.M. Radiosensitivity of human breast cancer cell lines of different hormonal responsiveness. Modulatory effects of oestradiol. Int. J. Radiat. Biol. 1996, 70:161-169.
19. Sarkaria J.N., Miller E.M., Parker C.J., Jordan V.C., Mulcahy R.T. 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res. Treat. 1994, 30:159-165.
20. Fisher B., Dignam J., Bryant J., DeCillis A., Wickerham D.L., Wolmark N., Costantino J., Redmond C., Fisher E.R., Bowman D.M., Deschenes L., Dimitrov N.V., Margolese R.G., Robidoux A., Shibata H., Terz J., Paterson A.H., Feldman M.I., Farrar W., Evans J., Lickley H.L. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. 1996, 88:1529-1542.
21. Fisher B., Dignam J., Wolmark N., Wickerham D.L., Fisher E.R., Mamounas E., Smith R., Begovic M., Dimitrov N.V., Margolese R.G., Kardinal C.G., Kavanah M.T., Fehrenbacher L., Oishi R.H. Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000.
22. Dalberg K., Johansson H., Johansson U., Rutqvist L.E. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Stockholm Breast Cancer Study Group. Cancer 1998, 82:2204-2211.
23. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Rabaglio M., Smith I., Wardley A., Price K.N., Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005, 353:2747-2757.
24. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., Paladini G., Mesiti M., Romeo D., Rinaldini M., Scali S., Porpiglia M., Benedetto C., Restuccia N., Buzzi F., Franchi R., Massidda B., Distante V., Amadori D., Sismondi P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol. 2005, 23:5138-5147.
25. Azria D., Larbouret C., Cunat S., Ozsahin M., Gourgou S., Martineau P., Evans D.B., Romieu G., Pujol P., Pelegrin A. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res. 2005, 7:R156-163.
26. Azria D., Belkacemi Y., Romieu G., Gourgou S., Gutowski M., Zaman K., Moscardo C.L., Lemanski C., Coelho M., Rosenstein B., Fenoglietto P., Crompton N.E., Ozsahin M. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol. 2010, 11:258-265.
27. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G., McCue B.L., Wakeling A.E., McClelland R.A., Manning D.L., Nicholson R.I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 1995, 87:746-750.
28. Pawlik T.M., Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:928-942.
29. Kastan M.B. Cell cycle. Checking two steps. Nature 2001, 410:766-767.
30. Mao Z., Jiang Y., Liu X., Seluanov A., Gorbunova V. DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia 2009, 11:683-691.
31. Choudhury A., Cuddihy A., Bristow R.G. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin. Radiat. Oncol. 2006, 16:51-58.
32. Lieber M.R. The mechanism of human nonhomologous DNA end joining. J. Biol. Chem. 2008, 283:1-5.